Key Takeaways
- • City Therapeutics, a blood clot-focused biotechnology firm, began public trading on Friday, October 16, 2026, after raising $200 million in an upsized initial public offering.
- • The IPO was steered by Goodwin Procter LLP and Cooley LLP, according to Law360.
- • The listing is part of a recent wave of biotechnology public offerings over the preceding few weeks.
Summary
City Therapeutics, a biotechnology company focused on blood clot treatments, began trading publicly on Friday after completing an upsized initial public offering that raised $200 million, according to Law360. The offering was steered by Goodwin Procter LLP and Cooley LLP.
The listing joins a recent wave of biotechnology IPOs that has come to market over the past few weeks, suggesting renewed investor appetite for clinical-stage life sciences issuers. The upsizing of the offering indicates that demand exceeded the initially planned deal size.
The available source material is limited to the opening of the Law360 report, and additional details such as the offering price, share count, lead underwriters, or clinical pipeline specifics were not available in the reporting reviewed.
The listing joins a recent wave of biotechnology IPOs that has come to market over the past few weeks, suggesting renewed investor appetite for clinical-stage life sciences issuers. The upsizing of the offering indicates that demand exceeded the initially planned deal size.
The available source material is limited to the opening of the Law360 report, and additional details such as the offering price, share count, lead underwriters, or clinical pipeline specifics were not available in the reporting reviewed.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.